Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015

for the Treatment of Patients with Spinal Muscular Atrophy CAMBRIDGE, Mass., March 29, 2018 – Scholar Rock, a biopharmaceutical company focused on developing medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role, today announced that the U.S. Food and Drug Administration… Att fortsätt läsa